MedTrace Logo

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19

NCT04530396 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 33758

Last updated 2021-01-22

No results posted yet for this study

Summary

Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults in the SARS-СoV-2 infection prophylactic treatment.

Conditions

  • Covid19 Prevention

Interventions

BIOLOGICAL

Gam-COVID-Vac

vaccine for intramuscular injection

OTHER

placebo

placebo comparator

Sponsors & Collaborators

  • Government of the city of Moscow

    collaborator UNKNOWN

  • CRO: Crocus Medical BV

    collaborator UNKNOWN

  • Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

    lead OTHER

Principal Investigators

  • Elena Smolyarchuk, MD, PhD · Study Coordinator

  • Sergey Zyryanov, MD, PhD · Study Coordinator

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
111 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2021-05-01
Completion
2021-05-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530396 on ClinicalTrials.gov